2021
Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China
Wu J, Sun B, Hou L, Guan F, Wang L, Cheng P, Scobell S, Cheng YC, Lam W. Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China. Frontiers In Pharmacology 2021, 11: 615287. PMID: 33716728, PMCID: PMC7947616, DOI: 10.3389/fphar.2020.615287.Peer-Reviewed Original ResearchTraditional Chinese medicineMaxingshigan decoctionChinese medicineCOVID-19COVID-19 patientsUnique medical needsPublic health measuresNovel coronavirus diseaseBradykinin stormConventional antiviralsHuo-XueAngiotensin systemSystemic inflammationAntiviral effectAntiviral actionIndividual herbsMedical needHealth measuresCoronavirus diseaseUnderlying mechanismOral formulaPathogenesisDiseaseProspective articlesBotanical treatments
2011
Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment
Wang E, Bussom S, Chen J, Quinn C, Bedognetti D, Lam W, Guan F, Jiang Z, Mark Y, Zhao Y, Stroncek DF, White J, Marincola FM, Cheng YC. Interaction of a traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironment. BMC Medical Genomics 2011, 4: 38. PMID: 21569348, PMCID: PMC3117677, DOI: 10.1186/1755-8794-4-38.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCamptothecinCell Line, TumorCell ProliferationColonic NeoplasmsDrug InteractionsDrugs, Chinese HerbalFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHep G2 CellsHumansImmunityImmunohistochemistryInflammationIrinotecanLiverMacrophagesMedicine, Chinese TraditionalMiceOrgan SizePolymerase Chain ReactionReproducibility of ResultsRNA, MessengerSignal TransductionSpleenTumor MicroenvironmentConceptsCPT-11Subcutaneous colon 38 tumoursChinese medicinePro-inflammatory pathwaysPre-clinical modelsColon 38 tumorsBDF-1 miceTraditional Chinese medicineRNA microarray technologyTumor rejectionInflammatory processPharmacodynamic propertiesAntitumor effectsSide effectsTCM formulaAnimal studiesPrevalent inductionTherapeutic effectivenessPHY906Tumor tissueTumor microenvironmentGood manufacturing practicesTumorsDistinct alterationsTissue-specific responses